Price Alert

Merus N.V. (MRUS)

NASDAQ: MRUS · Real-Time Price · USD

94.29

0.14 (0.15%)

At close: Oct 03, 2025, 3:59 PM

94.10

-0.20%

After-hours: Oct 03, 2025, 07:45 PM EDT

0.15% (1D)

Bid	94
Market Cap	7.13B
Revenue (ttm)	56.23M
Net Income (ttm)	-385.52M
EPS (ttm)	-5.58
PE Ratio (ttm)	-16.9
Forward PE	-19.25
Analyst	Hold
Dividends	n/a

Ask	94.3
Volume	3,865,443
Avg. Volume (20D)	1,609,452
Open	94.11
Previous Close	94.15
Day's Range	94.09 - 94.35
52-Week Range	33.19 - 94.56
Beta	1.26
Ex-Dividend Date	n/a

About MRUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRUS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Merus N.V. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

+35.97%

Merus shares are trading higher after Genmab agree... Unlock content with Pro Subscription

2 months ago

-2.83%

Merus shares are trading lower after the company reported worse-than-expected Q2 financial results.

News

4 days ago · businesswire.com

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...

5 days ago · benzinga.com

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...

5 days ago · barrons.com

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

5 days ago · businesswire.com

MRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Merus N.V. (NASDAQ: MRUS) to Genmab A/S for $97.00 per share is fair to Merus shareholder...

6 days ago · marketwatch.com

Months after cancer drug trial, Merus agrees to be bought at 41% premium

Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.

6 days ago · invezz.com

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...

6 days ago · reuters.com

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.

6 days ago · businesswire.com

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...

2 months ago · zacks.com

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.81 per share a year ago.

2 months ago · businesswire.com

Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions

NEW YORK--(BUSINESS WIRE)--Merus Global Investments (“Merus”), a multi-strategy investment partnership, today unveiled its refreshed website and announced a series of senior promotions and strategic a...

Load More News